Taro takeover can take long, says Sun Pharma

Image
BS Reporter New Delhi
Last Updated : Jan 19 2013 | 10:42 PM IST

Sun Pharma today said its proposed takeover of Taro Pharmaceuticals could take longer due to legal tussle, while rating the 'probability' of an out of court settlement with the Israeli company very low.

"Going by the behaviour displayed by Taro Pharmaceuticals, its director and the Levitt family and its passion for filing court cases, it appears that ultimate resolution for all issues involved is likely to take quite a bit of time," Sun Pharma Chairman and Managing Director Dilip Shanghvi said.

"I wanted to caution every body that its not something that will get over very soon," he added.

Shanghvi said several options exist before the company "to secure our long-term interests and we remain committed to the completion of this transaction".

Asked if the company would look for other options to grow inorganically of the litigation with Taro took longer, he said: "We don't have such a long timeline but we would continue to look for more opportunity."

Stating that the chances of an out of court settlement with Taro is minimal, he said :"If there was a possibility of settlement from our point of view then I don't think this would have gone into litigation."

He, however, said:"In business one answer is to never say no or that it is not possible, because everything is possible. But if you look at probabilities then I will not give any high probability of any settlement."

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 29 2008 | 1:49 PM IST

Next Story